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Background: Hypofractionated Radiosurgery (HR) is a therapeutic option for delivering partial brain radiotherapy
(RT) to large brain metastases or resection cavities otherwise not amenable to single fraction radiosurgery (SRS).
The use, safety and efficacy of HR for brain metastases is not well characterized and the optimal RT dose-
fractionation schedule is undefined.
Methods: Forty-two patients treated with HR in 3-5 fractions for 20 (48%) intact and 22 (52%) resected brain
metastases with a median maximum dimension of 3.9 cm (0.8-6.4 cm) between May 2008 and August 2011 were
reviewed. Twenty-two patients (52%) had received prior radiation therapy. Local (LC), intracranial progression free
survival (PFS) and overall survival (OS) are reported and analyzed for relationship to multiple RT variables through
Cox-regression analysis.
Results: The most common dose-fractionation schedules were 21 Gy in 3 fractions (67%), 24 Gy in 4 fractions (14%)
and 30 Gy in 5 fractions (12%). After a median follow-up time of 15 months (range 2-41), local failure occurred in 13
patients (29%) and was a first site of failure in 6 patients (14%). Kaplan-Meier estimates of 1 year LC, intracranial PFS,
and OS are: 61% (95% CI 0.53 – 0.70), 55% (95% CI 0.47 – 0.63), and 73% (95% CI 0.65 – 0.79), respectively. Local
tumor control was negatively associated with PTV volume (p = 0.007) and was a significant predictor of OS (HR 0.57,
95% CI 0.33 - 0.98, p = 0.04). Symptomatic radiation necrosis occurred in 3 patients (7%).
Conclusions: HR is well tolerated in both new and recurrent, previously irradiated intact or resected brain
metastases. Local control is negatively associated with PTV volume and a significant predictor of overall survival,
suggesting a need for dose escalation when using HR for large intracranial lesions.
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Brain metastases represent a significant cause of morbid-
ity and mortality among cancer patients. Partial brain
radiotherapy (RT) through stereotactic radiosurgery
(SRS) is an important therapeutic tool for the treatment
of brain metastases in multiple clinical settings. The
addition of SRS to whole brain radiation (WBRT) may
improve median survival and intracranial tumor control
when compared to WBRT alone in select patients [1,2],
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reproduction in any medium, provided the orfollowed by WBRT [3,4], and is commonly used as
salvage therapy for patients with intracranial tumor
progression after WBRT. Additionally, SRS is increas-
ingly used as a primary treatment modality in attempts
to prevent or delay the known neurocognitive toxicities
of WBRT [5]. Indeed, the benefits of radiosurgery are
well recognized, but all patients are not considered ac-
ceptable candidates for SRS.
Brain metastases larger than 3 cm in diameter or pro-
ducing more than 1 cm of midline shift are typically not
considered acceptable candidates for single fraction ra-
diosurgery [4] due to an insufficient volume response
and an increased risk for cerebral edema following SRS
[6-8]. Additionally, SRS may carry an increased toxicitytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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in close proximity to critical structures, such as the optic
chiasm or brainstem, and when the location of the me-
tastasis has previously received high radiation doses. In
these instances, hypofractionated radiosurgery (HR) de-
livered in 3-5 fractions over multiple days is an alterna-
tive therapeutic option for delivering partial brain RT.
HR may provide the benefit of improved local control
and reduced neurocognitive decline when compared to
WBRT, with reduced toxicity risk when compared to
SRS for large intracranial lesions or metastases in sensi-
tive locations. The use, safety and efficacy of HR is
supported by previously published series with short-term
follow up and varying radiation dose and fractionation
schedules described [9-19]. However, data reporting
long-term outcomes is limited and the optimal dose-
fractionation schedule for HR is undefined. The purpose
of this analysis is to evaluate the relationship between
RT dose-fractionation and clinical outcomes in a cohort
of patients with long-term imaging follow-up, who were
treated with HR at Emory University for brain metasta-
ses not amenable to SRS.
Materials and methods
Patient selection
With institutional review board approval, the treatment
records from the Radiation Oncology Department of
the Winship Cancer Institute of Emory University were
searched for patients having completed a planned course
of hypofractionated radiation therapy to the brain
consisting of >1 and ≤ 5 fractions. Patients with a diag-
nosis of secondary malignant neoplasms of the brain,
who were treated with or without surgical resection,
were included whether they had or had not received
prior radiation therapy to the treatment site. All treated
patients had a prior pathologic diagnosis of malignancy.
Patients without follow-up diagnostic MRI for outcome
assessment were excluded from analysis.
Hypofractionated radiation therapy
Patients underwent high-resolution treatment planning
MRI scan with and without contrast immediately before
or following CT simulation. Simulation was performed
in the supine position using an Aquaplast mask (WFR/
Aquaplast Corp., Wyckoff, NJ) for immobilization. The
treatment planning MRI was rigidly registered to the
simulation CT for improved target and normal tissue de-
lineation. For patients with intact brain metastases, the
gross tumor volume (GTV) was defined as the contrast
enhancing abnormality on the T1 post-contrast MRI se-
quence. For patients who had prior resection, the GTV
was designed to include the resection cavity as well as
any enhancing tumor. The clinical tumor volume (CTV)
was defined by expansion of the corresponding GTVwith 0 - 7 mm margin to account for potential micro-
scopic tumor extension and was modified according to
how well the tumor was visualized and the anatomic
location of the tumor to respect natural barriers to
tumor spread such as bone. A planning target volume
(PTV) was created to account for patient setup uncer-
tainty and target motion by the addition of a 0 – 3 mm
margin to the CTV. Median total margins for GTV to
PTV expansion was 2 mm (range 0 - 10 mm). Zero ex-
pansion margin was used in 2 patients who had previ-
ously received radiation therapy and in which the GTV
abutted the brainstem. Conversely, the largest total ex-
pansion margin of 10 mm (7 mm GTV to CTV and
3 mm CTV to PTV) was used in one patient with a
poorly visualized resection cavity.
Radiation therapy dose and fractionation was pre-
scribed at the discretion of the treating physician. For
the purpose of dose-response analysis, radiation therapy
dose was converted to biological equivalent dose (BED)
[20] and single fraction equivalent dose (SFED) [21]
using the following equations where D equals total dose
and d equals dose per fraction, assuming an α/β ratio of
10 for tumor control and a Dq of 1.8 [21].
BED ¼ D  1þ d= a=βð Þ½ 
SFED ¼ D− n 1ð Þ  Dq
The prescription dose was prescribed such that at least
95% of the PTV received 100% of the prescribed dose.
Registration and contouring were carried out with Vel-
ocity AI (Velocity Medical Systems, Atlanta, GA) and
dose calculation was done with Eclipse (Varian Medical
Systems, Palo Alto, CA). Patients underwent cone beam
CT scans using 6 degrees of freedom registration for
precise positioning prior to therapy [22]. Multifield (>10
fields) intensity modulated radiotherapy (IMRT) or dy-
namic conformal arcs (DCA) with photons of 6MV were
used for treatment delivery.
Follow-up and outcomes analysis
Patients were routinely followed by history, physical
exam and MRI, with and without contrast, initially at 4-
6 weeks after completion of radiotherapy and every 2-3
months thereafter, or at the first incidence of symptom-
atic progression. Intracranial failure was defined as
tumor recurrence or progression within the brain, as
was evident by diagnostic MRI. Failure was considered
local if >90% of the tumor recurrence was within the
prescription isodose volume, distant if >90% of the re-
current tumor was outside the prescription isodose and
marginal if neither local nor distant. Radiation necrosis
was diagnosed by increased enhancement on T1 post-
contrast MRI with or without surrounding abnormal
T2/FLAIR signal abnormality, which corresponded with
Table 1 Patient, tumor and previous RT characteristics
n = 42 patients n (%)
Median (range)





ECOG 0-2 37 (88%)
ECOG 3-4 5 (12%)
Primary Cancer Diagnosis
Breast 12 (29%)
Lung, NSCLC 10 (24%)
Melanoma 9 (21%)
Head and Neck 5 (12%)
Other/Unknown 6 (14%)
Intact Brain Metastasis 20 (48%)




GTV/Cavity Maximum Dimension 3.9 cm (0.8-6.4 cm)
GTV/Cavity Volume 13.6 cc (0.2 – 57.0 cc)
PTV Volume 24.5 cc (0.8 – 122.0 cc)









41.25 Gy (10 -75)
Time from Previous RT to HR 13 months (0.3-32.4)
Abbreviation: NSCLC, non-small cell lung cancer.
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perfusion images and did not progress rapidly on serial
MRIs, or was confirmed by surgical specimen. Patients
with tumor progression and/or radiation necrosis were
frequently reviewed at central nervous system multi-
disciplinary tumor board for consensus diagnosis.
Statistical analysis
Descriptive statistics were compiled to characterize the
patient population. Kaplan-Meier analysis was used to
estimate overall survival and freedom from local failure,
intracranial progression, and radiation necrosis. Survival
analysis was calculated from time of radiation therapy
initiation until first evidence of local failure, intracranial
failure, or death. For alive patients, overall survival was
censored at last follow-up, and intracranial progression
free survival, local control, and freedom from radiation
necrosis were censored at last follow-up MRI of the
brain or at the time of subsequent WBRT. Cox-
regression analysis was used to assess the significance of
multiple radiation therapy and tumor variables, includ-
ing GTV/cavity size, PTV volume, dose per fraction,
total dose, BED10, SFED, previous radiation therapy re-
ceived, and resected vs. unresected tumor on local con-
trol, overall survival, and freedom from radiation
necrosis. All statistical tests were 2 sided and performed




Forty-seven patients treated with HR for new or pro-
gressive brain metastases or resection cavities between
May 2008 and August 2011 at the Emory Clinic were
identified, and 42 of these patients were included for
outcomes analysis. Five patients were excluded due to
lack of post-treatment imaging follow-up. Table 1 in-
cludes patient, tumor and previous treatment character-
istics. The most common indication for the use of HR
was large tumor or resection cavity size. Additionally,
patients not considered acceptable candidates for single
fraction SRS due to close proximity of the tumor to crit-
ical structures such as the optic chiasm, optic nerves, or
brainstem were also included.
Radiation therapy
Total radiation dose delivered ranged from 21-30 Gy, in
5-7 Gy per fraction for 3-5 fractions over a median treat-
ment time of 7 days (range 3 – 14). In 4 patients status-
post a subtotal resection, a simultaneous infield boost of
an additional 1 – 1.5 Gy per fraction was delivered to the
gross residual disease. Table 2 lists the dose-fractionation
schedules used. All patients completed the prescribed
radiation course as planned.Intracranial control and patterns of failure
The median imaging follow-up of this study was
8 months (range 1- 41). KM estimates of 1 year LC and
intracranial PFS are 61% (95% CI 0.53 – 0.70) and 55%
(95% CI 0.47 – 0.63), respectively (Figure 1). On univari-
ate analysis, local failure was significantly associated with
GTV/Cavity maximum dimension (p = 0.037) and PTV
volume (p = 0.007, Table 3). No statistically significant
association was found between LC and dose per fraction,
total dose, biological equivalent dose (BED), single frac-
tion equivalent dose (SFED), previous RT received, or
Figure 1 Kaplan-Meier curves of local control, freedom from
intracranial progression and overall survival.
Table 2 HR fractionation schedules
Fractionation schedule
n = 42 patients
n (%) BED10 SFED
(Gy)
7 Gy x 3* 28 (67) 37.5 17.4
6 Gy x 4** 6 (14) 38.4 18.6
6 Gy x 5 5 (12) 48 22.8
5 Gy x 5 2 (4) 37.5 17.8
5 Gy x 6 1 (2) 45 21
*Three patients status-post subtotal resection (STR) received 7 Gy x 3 to the
PTV with a simultaneous infield boost (SIB) to the GTV for an additional 1 Gy
per fraction. ** One patient status-post STR received 6 Gy x 4 to the PTV with a
SIB to the GTV for an additional 1.5 Gy per fraction.
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analysis was not performed given the only significant
variables were both measures of tumor size.
At last follow-up, 18 patients (48%) were free from any
intracranial failure. Among the 24 patients with intracra-
nial progression, site of first recurrences was isolated
distant failure in 13 (50%), local failure in 5 (23%), mar-
ginal failure in 1 (2%), and distant failure occurring sim-
ultaneously with local failure in 4 (18%) or with
marginal failure in 1 (2%). Distant intracranial failure
was thus the predominant site of first intracranial pro-
gression, occurring in 16 patients (73%).
In total, 10 patients received salvage radiotherapy for
intracranial tumor progression after HR. Three patients
(7%), two with local and distant intracranial failure and
one with distant intracranial failure alone, received sal-
vage WBRT at a median time of 4.7 months (range 3-7)
after completion of HR. Six patients (14%), one with
local and distant intracranial failure and 5 with distant
intracranial failure alone, receive salvage SRS at a me-
dian time of 15.5 months (range 2- 34) after completion
of HR. One patient with local and distant intracranial
failure received salvage WBRT with SRS boost to the site
of distant failure at 1.5 months after completion of HR.
Seven patients with local intracranial failure did not re-
ceive salvage RT to the local site due to the high cumu-
lative dose received between HR and previous brain RT
(median 76 Gy, range 60 - 85.5 Gy), and two patients
with local intracranial failure did not receive salvage
local RT due to systemic disease progression and poor
prognosis.
Overall survival
After a median follow-up of 15 months (range 2 -
41 months), median survival has not been reached. KM
estimate 1 year overall survival is 73% (95% CI 0.65 –
0.79, Figure 2). Survival was significantly associated with
whether HR was delivered as first therapy or salvage
treatment after prior RT (p = 0.04) and with local tumor
control (p = 0.01) on univariate analysis. After account-
ing for initial versus salvage treatment, local control
Table 3 Cox-regression analysis of the relationship
between freedom from local failure and multiple tumor
and RT variables
Variable Freedom from local failure
Uni-variate
(p)
GTV/Cavity Max Dimension 0.037
PTV Volume 0.007




First RT vs. Salvage RT 0.241
Cavity vs. Solid Tumor 0.992
Figure 3 Kaplan-Meier curve of freedom from radiation
necrosis.
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0.33 - 0.98, p = 0.04). Patients with local failure had a
median OS of 6 months, while median survival was not
reached in patients without local failure. At last follow-
up, 27 (64%) are alive and 15 of the alive patients (56%)
have stable intracranial disease. Fifteen patients (36%)
have died, of whom 9 patients (60%) have died with
progressive intracranial disease.
Treatment toxicity
The KM estimate of freedom from radiation necrosis at
1 year is 90% (CI 0.84 – 0.96), (Figure 3). No association
was found between the incidence of radiation necrosisFigure 2 Kaplan-Meier curve of overall survival in relationship
to local tumor control.and previous RT received, total dose, dose per fraction,
BED, SFED, PTV volume, or resection cavity vs. solid
tumor. Four patients (9.5%) were diagnosed with radi-
ation necrosis by follow-up imaging, and 3 of these pa-
tients (7%) were symptomatic requiring oral steroids.
One asymptomatic patient underwent surgical resection
for suspected tumor recurrence and was found to have
radiation necrosis on final pathology.
Discussion
With long-term follow-up, our data demonstrates that
HR is well tolerated in both new and previously irradi-
ated, intact or resected brain metastases and represents
a promising therapeutic option for these patients who
are not otherwise considered candidates for single frac-
tion SRS. One-year estimates of local control, intracra-
nial progression free survival and overall survival in our
series were 61%, 55%, and 73%, respectively, while the
rate of symptomatic radiation necrosis was only 7% (3 of
42 patients). Thus, our data adds to the previously pub-
lished literature supporting the use of HR for brain me-
tastases and represents excellent outcomes considering
the fact that the tumors in our series were considerably
larger than in other reported series and were heavily
pre-treated, with the majority having received prior radi-
ation therapy to the HR treatment site (Table 4).
We found local control to be negatively associated
with PTV volume. This finding is in agreement with
previously published analyses of both SRS and HR,
which demonstrated decreased local control and tumor









Aoki et al. [7] 44/65 - 5-6 Gy x 3-5 72% at 1 year 2% grade 3
Aoyama et al. [8] 87/159 3.3 cc 8.75 Gy x 4 81% at 1 year 7% grade 3
DePotter et al. [9] 35/58 8.6 cc WBRT + 6 Gy x 5 66% at 1 year 11% grade 3
Fahrig et al. [17] 150/228 6.1 cc 6-7 Gy x 5 - 22%
5 Gy x 7 - 7%
10 Gy x 4 - 0%
Giubilei et al. [10] 30/44 2.1 cm/4.8 cc 6 Gy x 3/ 8 Gy x 4 86% at 1 year -
Kwon et al. [11] 27/52 1.2 cm/0.5 cc 20-35 Gy in 4-6 68% at 1 year 5.8% radiation necrosis
Lindvall et al. [12] 47/47 - 8 Gy x 5 84% crude 6.25% radiation necrosis, 1 patient death
Narayana et al. [13] 20/20 - 6 Gy x 5 70% at 1 year 15%
Ogura et al. [14] 39/46 1.8 cm 7 Gy x 5 or 17% at 1 year 2.5% grade 3
WBRT + 4-5 Gyx5
Wang et al. [15] 37/37 cavity > 3 cm 8 Gy x 3 80% at 6 months 9%
Current Study 42/42 3.9 cm/13.6 cc 5-8 Gy x 3-5 62% at 1 year 7% radiation necrosis
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the median GTV to PTV expansion was only 2 mm.
Thus the PTV volume was predominantly reflective of
GTV size, which was also found to be negatively associ-
ated with local control. In total, in-field tumor recur-
rence occurred in 9 patients with only 2 patients
experiencing tumor recurrence marginal to the treat-
ment volume. The predominance of in-field local recur-
rences suggests marginal misses due to insufficient
expansion margins is not a major contributor to the
incidence of tumor recurrence. Indeed, the frameless
radiosurgery technique with 6 degrees of freedom regis-
tration used herein has previously been demonstrated to
have an accuracy and reproducibility of less than 1 mm
[22,23]. The importance of precise positioning and
immobilization in the treatment of these large intracra-
nial lesions with highly conformal RT is important for
both maintaining tumor control and minimizing the
dose delivered to normal brain.
Although higher dose per fraction was not associated
with improved local control, this may be explained by
the fact that the higher dose per-fraction regimen most
commonly used in this series, 7 Gy x 3, has a lower BED
and SFED compared with the other regimens used
(Table 2). In the only other published HR series to com-
pare different dose-fractionation schemes, Fahrig et al.
[19] demonstrated higher rates of complete response
in tumors treated with 6-7 Gy x 5 or 5 Gy x 7 versus
4 Gy x 10. These findings suggest dose escalation may
be of benefit when using HR for larger intracranial
tumors. The significant association between local tumor
control and overall survival in this series further high-
lights the need for dose optimization.In the only prospective trial of HR for the treatment of
brain metastasis, Ernst-Stecken et al. [18] used either
HR alone (7 Gy x 5) or WBRT followed by an HR boost
(boost dose 6 Gy x 5) for patients with 1-4 brain metas-
tases larger than 3 cc and controlled extracranial disease.
Results revealed a 2.8% rate of progressive disease after a
median follow-up of 7 months. This rate of local failure
is considerably lower than has been demonstrated in our
and other retrospective series, and appeared to be asso-
ciated with increased toxicity as 49% of patients (25 of
51) experienced symptoms associated with radiologic
signs of increased edema requiring steroid medication.
From this analysis, it was found that the volume of nor-
mal brain receiving ≥ 4 Gy per fraction (V4Gy) was sig-
nificantly associated with the incidence of radiation
necrosis. In pursuit of the excellent tumor control dem-
onstrated in this Phase II trial, a prospective phase I
dose-escalation trial performed within the limitations of
the aforementioned dose constraint is required to deter-
mine the maximum tolerated dose, maximum tolerated
dose that will maximize patient benefits and minimize
associated risks in the use of HR for large brain metasta-
ses. With this purpose in mind, we have initiated an in-
stitutional phase-1 dose escalation protocol of HR for
large brain metastasis ≥ 3 cm and ≤ 6 cm to be treated
in 5 fractions, delivered in 2-3 fractions per week
(NCT01705548).
Our data is limited in that the population is small and
heterogeneous and the analysis is subject to the multiple
potential confounding biases and limitations inherent to
any retrospective review. Safety may be overestimated in
a retrospective study and toxicity analysis is primarily
limited to clearly documented diagnoses of radiation
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treatment MRI imaging is a strength of this analysis.
The various dose-fractionation schedules used in our
series gave us the unique ability to compare clinical out-
comes with RT dose, and although no significant diffe-
rence in local control or radiation necrosis were seen
among the patients treated with the different dose-
fractionation regimens, in light of the higher BED and
SFED of 6 Gy x 5 and the results demonstrated with this
regimen in our series and others [7,9,17], we recom-
mend 6 Gy x 5 as the future HR treatment schedule
used outside of a prospective protocol.
Conclusions
The use of hypofractionated radiosurgery for the treat-
ment of both new and previously irradiated, intact or
resected, brain metastases is well tolerated and leads to
good local tumor control with excellent overall survival.
Local control was negatively associated with PTV vol-
ume and significantly predicted for overall survival. We
recommend 6 Gy x 5 be used to deliver HR for large
intracranial tumors and further dose escalation in a
controlled, prospective trial may be of benefit.
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